AI ASSISTANT
Ask DrugCentral
Explore drug information in your own words.
Type a question in the search bar above to get started. Each question is answered independently.
Try a sample question
Select a question to fill the search bar, then submit it or edit it first.
AI can make mistakes. Verify answers against the original sources before relying on them.
nafcillin 🐶 Veterinary Use | Indications/Contra | FAERs-F | FAERs-M | Orange Bk | PK/Tox | Related Drugs | BioActivity |
| Stem definition | Drug id | CAS RN |
|---|---|---|
| antibiotics, 6-aminopenicillanic acid derivatives | 1869 | 147-52-4 |
Description:
| Molecule | Description |
|---|---|
|
Synonyms:
|
A semi-synthetic antibiotic related to penicillin.
Legend: OFP - off patent OFM - off market ONP - on patent |
Drug dosage:
| Dose | Unit | Route |
|---|---|---|
| 3 | g | P |
ADMET properties:
| Property | Value | Reference |
|---|---|---|
| BDDCS (Biopharmaceutical Drug Disposition Classification System) | 3 | Benet LZ, Broccatelli F, Oprea TI |
| EoM (Fraction excreted unchanged in urine) | 27 % | Benet LZ, Broccatelli F, Oprea TI |
| MRTD (Maximum Recommended Therapeutic Daily Dose) | 188.60 µM/kg/day | Contrera JF, Matthews EJ, Kruhlak NL, Benz RD |
| BA (Bioavailability) | 30 % | Kim MT, Sedykh A, Chakravarti SK, Saiakhov RD, Zhu H |
| Vd (Volume of distribution) | 0.22 L/kg | Lombardo F, Berellini G, Obach RS |
| CL (Clearance) | 3.30 mL/min/kg | Lombardo F, Berellini G, Obach RS |
| fu (Fraction unbound in plasma) | 0.13 % | Lombardo F, Berellini G, Obach RS |
| t_half (Half-life) | 0.70 hours | Lombardo F, Berellini G, Obach RS |
| S (Water solubility) | 50 mg/mL | Bocci G, Oprea TI, Benet LZ |
Predicted pharmacokinetic/toxicological properties (PK-AZ):
| Property | Description | Value | Unit | Confidence | Similarity |
|---|---|---|---|---|---|
| azlogd74 | LogD at pH 7.4 | 0.058 | High | 1 | |
| caco2-efflux | Caco-2 efflux ratio (BA/AB) | 10.423 | High | 1 | |
| caco2-intrinsic-papp | Caco-2 intrinsic apparent permeability | 1.982 | 10^-6 cm/s | High | 1 |
| dh-clint | Dog hepatocyte intrinsic clearance | 3.199 | uL/min/10^6 cells | High | 1 |
| dppb | Dog plasma protein binding (% unbound) | 17.450 | % | High | 1 |
| fcs-ppb | Fetal calf serum protein binding (% unbound) | 18.500 | % | High | 1 |
| herg | hERG pIC50 | 4.381 | pIC50 | High | 1 |
| hh-clint | Human hepatocyte intrinsic clearance | 2.786 | uL/min/10^6 cells | High | 1 |
| hlm-clint | Human liver microsomal intrinsic clearance | 3.673 | uL/min/mg protein | High | 1 |
| hppb | Human plasma protein binding (% unbound) | 12.450 | % | High | 1 |
| kinase-safety-class | ACVR2A,ACVR2B,AURKA,AXL,BRAF,BTK,CAMK2B,CAMK2D,CDK5,CDK9,DDR1,DYRK1B,EGFR,EIF2AK3,ERBB2,GRK2,GRK3,GSK3B,ITK,JAK2,JAK3,MAP2K6,MAP3K21,MAP3K7,MAPK10,MAPK7,MAPK9,MAPKAPK2,NTRK2,PDK1,PDK2,PDK4,PIK3CA,PIK3CB,PIK3CG,PIM2,PRKDC,STK33,SYK,TEK,TGFBR1,TTK,ZAP70 | 43 | |||
| kinase-selectivity-class | ACVR2B,AXL,BRAF,GRK2,MAP2K6 | 5 | |||
| mdck-mdr1-efflux | MDCK-MDR1 efflux ratio | 2.291 | High | 1 | |
| mh-clint | Mouse hepatocyte intrinsic clearance | 17.100 | High | 1 | |
| mppb | Mouse plasma protein binding (% unbound) | 11.620 | High | 1 | |
| nih-mdck-mdr1-efflux | NIH MDCK-MDR1 efflux ratio | 5.082 | High | 1 | |
| pfas-class | PFAS structural alert (1 = True, 0 = False) | 0 | |||
| pppb | Pig plasma protein binding (% unbound) | 12.990 | % | High | 1 |
| rh-clint | Rat hepatocyte intrinsic clearance | 6.950 | uL/min/10^6 cells | High | 1 |
| rh-fuinc | Rat hepatocyte fraction unbound in incubation | 73 | % | High | 1 |
| rppb | Rat plasma protein binding (% unbound) | 8.660 | % | High | 1 |
| solubility-dd | Solubility at pH 7.4 in DMSO | 926.830 | uM | High | 1 |
Approvals:
| Date | Agency | Company | Orphan |
|---|---|---|---|
| Oct. 11, 1965 | FDA | WYETH AYERST |
FDA Adverse Event Reporting System (Female)
None
FDA Adverse Event Reporting System (Male)
| MedDRA adverse event term | Likelihood ratio | Likelihood ratio threshold | Patients taking drug having adverse event | Patients taking drug not having adverse event | Patients not taking drug having adverse event | Patients not taking drug not having adverse event |
|---|---|---|---|---|---|---|
| Tubulointerstitial nephritis | 131.28 | 37.22 | 41 | 821 | 31507 | 42588966 |
| Acute kidney injury | 68.04 | 37.22 | 57 | 805 | 367280 | 42253193 |
FDA Adverse Event Reporting System (Geriatric)
| MedDRA adverse event term | Likelihood ratio | Likelihood ratio threshold | Patients taking drug having adverse event | Patients taking drug not having adverse event | Patients not taking drug having adverse event | Patients not taking drug not having adverse event |
|---|---|---|---|---|---|---|
| Tubulointerstitial nephritis | 147.73 | 36.46 | 44 | 1141 | 54240 | 110533874 |
| Acute kidney injury | 78.60 | 36.46 | 60 | 1125 | 635370 | 109952744 |
FDA Adverse Event Reporting System (Pediatric)
None
Pharmacologic Action:
| Source | Code | Description |
|---|---|---|
| ATC | J01CF06 | ANTIINFECTIVES FOR SYSTEMIC USE ANTIBACTERIALS FOR SYSTEMIC USE BETA-LACTAM ANTIBACTERIALS, PENICILLINS Beta-lactamase resistant penicillins |
| FDA CS | M0016152 | Penicillins |
| FDA EPC | N0000175497 | Penicillin-class Antibacterial |
| MeSH PA | D000890 | Anti-Infective Agents |
| MeSH PA | D000900 | Anti-Bacterial Agents |
| CHEBI has role | CHEBI:33282 | antibacterial agent |
| CHEBI has role | CHEBI:35441 | antiinfective agent |
| CHEBI has role | CHEBI:36047 | antibacterial drug |
Related Drugs by ATC class:
J01CF Beta-lactamase resistant penicillins 5 drugs
Drug Use | Suggest Off label Use Form| |View source of the data|
| Disease | Relation | SNOMED_ID | DOID |
|---|---|---|---|
| Staphylococcal meningitis | indication | 12166008 | |
| Infection of skin AND/OR subcutaneous tissue | indication | 19824006 | |
| Staphylococcal pneumonia | indication | 22754005 | |
| Staphylococcal infectious disease | indication | 56038003 | |
| Staphylococcal endocarditis | indication | 73028002 | |
| Acute bacterial sinusitis | indication | 75498004 | |
| Infection of bone | indication | 111253001 | |
| Infection due to Staphylococcus aureus | indication | 406602003 | |
| Osteomyelitis due to Staphylococcus aureus | indication | 428783003 | |
| Sepsis due to Staphylococcus aureus | indication | 448417001 | |
| Staphylococcus Aureus Joint Infection | indication | ||
| Staphylococcal Prosthetic Heart Valve Endocarditis | indication | ||
| Pyrexia of unknown origin | off-label use | 7520000 | |
| Kidney disease | contraindication | 90708001 | DOID:557 |
| Infectious mononucleosis | contraindication | 271558008 | DOID:8568 |
| Pseudomembranous enterocolitis | contraindication | 397683000 |
🐶 Veterinary Drug Use
None
🐶 Veterinary products
None
Acid dissociation constants calculated using MoKa v3.0.0
| Dissociation level | Dissociation constant | Type (acidic/basic) |
|---|---|---|
| pKa1 | 2.76 | acidic |
Orange Book patent data (new drug applications)
None
Orange Book exclusivity data (new drug applications)
None
Bioactivity Summary:
| Target | Class | Pharos | UniProt | Action | Type | Activity value (-log[M]) | Mechanism action | Bioact source | MoA source |
|---|---|---|---|---|---|---|---|---|---|
| Penicillin-binding protein | Enzyme | INHIBITOR | CHEMBL | CHEMBL | |||||
| Penicillin-binding protein 1A | Enzyme | WOMBAT-PK |
External reference:
| ID | Source |
|---|---|
| 4018987 | VUID |
| N0000178981 | NUI |
| D00928 | KEGG_DRUG |
| 7177-50-6 | SECONDARY_CAS_RN |
| 4018987 | VANDF |
| 4019849 | VANDF |
| CHEBI:7447 | CHEBI |
| NFN | PDB_CHEM_ID |
| CHEMBL1443 | ChEMBL_ID |
| CHEMBL1568276 | ChEMBL_ID |
| 10942 | IUPHAR_LIGAND_ID |
| DB00607 | DRUGBANK_ID |
| 4CNZ27M7RV | UNII |
| 218589 | RXNORM |
| 2025 | MMSL |
| 3048 | MMSL |
| 5145 | MMSL |
| d00029 | MMSL |
| 002698 | NDDF |
| 004837 | NDDF |
| 372898000 | SNOMEDCT_US |
| 55435000 | SNOMEDCT_US |
| 91169009 | SNOMEDCT_US |
| C0027324 | UMLSCUI |
| D009254 | MESH_DESCRIPTOR_UI |
| 1491 | INN_ID |
| 8982 | PUBCHEM_CID |
Pharmaceutical products:
| Product | Category | Ingredients | NDC | Form | Quantity | Route | Marketing | Label |
|---|---|---|---|---|---|---|---|---|
| NAFCILLIN | HUMAN PRESCRIPTION DRUG LABEL | 1 | 0338-1017 | INJECTION, SOLUTION | 1 g | INTRAVENOUS | NDA | 23 sections |
| NAFCILLIN | HUMAN PRESCRIPTION DRUG LABEL | 1 | 0338-1019 | INJECTION, SOLUTION | 2 g | INTRAVENOUS | NDA | 23 sections |
| Nafcillin | HUMAN PRESCRIPTION DRUG LABEL | 1 | 23155-906 | INJECTION, POWDER, FOR SOLUTION | 1 g | INTRAMUSCULAR | ANDA | 14 sections |
| Nafcillin | HUMAN PRESCRIPTION DRUG LABEL | 1 | 23155-907 | INJECTION, POWDER, FOR SOLUTION | 2 g | INTRAMUSCULAR | ANDA | 14 sections |
| Nafcillin | HUMAN PRESCRIPTION DRUG LABEL | 1 | 25021-198 | INJECTION, POWDER, FOR SOLUTION | 10 g | INTRAVENOUS | ANDA | 25 sections |
| Nafcillin | HUMAN PRESCRIPTION DRUG LABEL | 1 | 36000-175 | INJECTION | 1 g | INTRAMUSCULAR | ANDA | 26 sections |
| Nafcillin | HUMAN PRESCRIPTION DRUG LABEL | 1 | 36000-176 | INJECTION | 2 g | INTRAMUSCULAR | ANDA | 26 sections |
| Nafcillin | HUMAN PRESCRIPTION DRUG LABEL | 1 | 44567-221 | POWDER, FOR SOLUTION | 1 g | INTRAMUSCULAR | ANDA | 25 sections |
| Nafcillin | HUMAN PRESCRIPTION DRUG LABEL | 1 | 44567-222 | POWDER, FOR SOLUTION | 2 g | INTRAMUSCULAR | ANDA | 25 sections |
| Nafcillin | HUMAN PRESCRIPTION DRUG LABEL | 1 | 44567-223 | INJECTION, POWDER, FOR SOLUTION | 10 g | INTRAVENOUS | ANDA | 13 sections |
| Nafcillin | Human Prescription Drug Label | 1 | 55150-122 | INJECTION, POWDER, FOR SOLUTION | 1 g | INTRAMUSCULAR | ANDA | 23 sections |
| Nafcillin | Human Prescription Drug Label | 1 | 55150-123 | INJECTION, POWDER, FOR SOLUTION | 2 g | INTRAMUSCULAR | ANDA | 23 sections |
| Nafcillin | Human Prescription Drug Label | 1 | 55150-123 | INJECTION, POWDER, FOR SOLUTION | 2 g | INTRAMUSCULAR | ANDA | 23 sections |
| Nafcillin | Human Prescription Drug Label | 1 | 55150-124 | INJECTION, POWDER, FOR SOLUTION | 10 g | INTRAVENOUS | ANDA | 23 sections |
| Nafcillin | Human Prescription Drug Label | 1 | 55150-124 | INJECTION, POWDER, FOR SOLUTION | 10 g | INTRAVENOUS | ANDA | 23 sections |
| Nafcillin | HUMAN PRESCRIPTION DRUG LABEL | 1 | 63323-327 | INJECTION, POWDER, LYOPHILIZED, FOR SOLUTION | 1 g | INTRAVENOUS | ANDA | 13 sections |
| Nafcillin | HUMAN PRESCRIPTION DRUG LABEL | 1 | 63323-328 | INJECTION, POWDER, LYOPHILIZED, FOR SOLUTION | 2 g | INTRAMUSCULAR | ANDA | 13 sections |
| Nafcillin | HUMAN PRESCRIPTION DRUG LABEL | 1 | 63323-328 | INJECTION, POWDER, LYOPHILIZED, FOR SOLUTION | 2 g | INTRAMUSCULAR | ANDA | 13 sections |
| Nafcillin | HUMAN PRESCRIPTION DRUG LABEL | 1 | 63323-330 | INJECTION, POWDER, FOR SOLUTION | 10 g | INTRAVENOUS | ANDA | 13 sections |
| NAFCILLIN SODIUM | HUMAN PRESCRIPTION DRUG LABEL | 1 | 72485-405 | INJECTION, POWDER, FOR SOLUTION | 1 g | INTRAMUSCULAR | ANDA | 21 sections |
| NAFCILLIN SODIUM | HUMAN PRESCRIPTION DRUG LABEL | 1 | 72485-406 | INJECTION, POWDER, FOR SOLUTION | 2 g | INTRAMUSCULAR | ANDA | 21 sections |
| Nafcillin | Human Prescription Drug Label | 1 | 72603-211 | INJECTION, POWDER, FOR SOLUTION | 1 g | INTRAMUSCULAR | ANDA | 23 sections |
| Nafcillin | Human Prescription Drug Label | 1 | 72603-453 | INJECTION, POWDER, FOR SOLUTION | 2 g | INTRAMUSCULAR | ANDA | 23 sections |
| Nafcillin | HUMAN PRESCRIPTION DRUG LABEL | 1 | 72603-567 | INJECTION, POWDER, FOR SOLUTION | 10 g | INTRAVENOUS | ANDA | 12 sections |
| NAFCILLIN SODIUM | HUMAN PRESCRIPTION DRUG LABEL | 1 | 83270-309 | INJECTION, POWDER, FOR SOLUTION | 1 g | INTRAVENOUS | ANDA | 21 sections |
| NAFCILLIN SODIUM | HUMAN PRESCRIPTION DRUG LABEL | 1 | 83270-310 | INJECTION, POWDER, FOR SOLUTION | 2 g | INTRAMUSCULAR | ANDA | 21 sections |
| Nafcillin | HUMAN PRESCRIPTION DRUG LABEL | 1 | 83634-101 | INJECTION, POWDER, FOR SOLUTION | 10 g | INTRAVENOUS | ANDA | 24 sections |